Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC
Live and Live-Streamed Symposium at ESMO Immuno-Oncology Annual Congress 2022
To attend this program, you must be registered for the ESMO Immuno-Oncology Congress 2022 Meeting
Dates
Thursday, December 8th, 2022
17:45 – 18:45 CET
Location
Palexpo | Room A
30 Route François-Peyrot
1218 Le Grand-Saconnex
Geneva, Switzerland
Overview
This CME satellite symposium will highlight the utilization of immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with non-small cell lung cancer (NSCLC). The expert faculty, led by Professor Solange Peters, will first review the scientific advances for the identification of NSCLC biomarkers and associated serum and immunohistochemistry testing. Next, a review of the latest clinical trial data for biomarker-driven targeted therapeutics, will be discussed. Following, the faculty will discuss treatment strategies that account for the role of CEACAM5 targeted therapeutics to improve outcomes in patients with CEA-positive NSCLC. To conclude, the faculty will hold a panel discussion to further delve into targeted therapeutics to optimize patient outcomes.
Agenda
I. Welcome & Introductions – Solange Peters, MD, PhD
II. Identification of NSCLC Biomarkers and Associated Serum and Immunohistochemistry Testing – Hossein Borghaei, DO, MS
III. Clinical Trial Review for Biomarker-Driven Targeted Therapeutics, Including CEACAM5 for Patients with NSCLC – Natasha Leighl, MD
IV. The Role of CEACAM5-Targeted Therapeutics to Improve Outcomes in Patients with CEA-Positive NSCLC – David Planchard, MD
V. Faculty Panel Discussion – All Faculty
Faculty
Solange Peters, MD, PhD (Course Chair)
Medical Oncology Chair
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Fox Chase Cancer Center
Philadelphia, PA
Natasha B. Leighl, BSc, MMSc, MD
Clinician Investigator
Cancer Clinical Research Unit (CCRU)
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
David Planchard, MD, PhD
Thoracic Oncologist
Head of Thoracic Group
Department of Medical Oncology
Institut Gustave Roussy (IGR)
Villejuif, France
JointAccreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this live material for a maximum of 1.0 European CME Credit® (ECMECs). AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Sanofi
Provided by:
